Beam Therapeutics develops precision genetic medicines using base editing technology to enable targeted modifications of DNA sequences. This approach addresses the limitations of traditional gene editing methods, offering potential treatments for genetic disorders with improved accuracy and reduced off-target effects.
Funding
$260M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional gene editing techniques can be imprecise, leading to unintended DNA modifications and potential off-target effects, which limits their safety and efficacy in treating genetic disorders. Existing methods may also be inefficient in correcting certain types of mutations, hindering the development of effective therapies for a wide range of genetic diseases.
Solution
Beam Therapeutics is developing precision genetic medicines using base editing technology to enable targeted and irreversible modifications of single DNA bases, such as converting a C to a T or an A to a G. This approach offers a more precise way to correct disease-causing mutations, minimizing off-target effects compared to traditional gene editing methods that cut both DNA strands. Beam's base editing platform aims to expand the potential of genetic medicine by addressing a broader range of genetic disorders with improved accuracy and reduced safety concerns. The company is also developing a suite of delivery technologies, including electroporation, nonviral, and viral modalities, to effectively deliver base editors to target cells and tissues.
Target Audience
The primary target audience includes patients with genetic disorders and the biopharmaceutical industry seeking more precise and safer gene editing tools.
Features
- Base editing technology for precise and irreversible modification of single DNA bases
- Minimizes off-target effects compared to traditional gene editing methods
- Development of a suite of delivery technologies, including electroporation, nonviral, and viral modalities